A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.

Int J STD AIDS. 1995 Jan-Feb;6(1):19-26. Unique Identifier : AIDSLINE MED/95244659
Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD; George NJ; Britton DJ; AIDS Center, St Vincent's Hospital and Medical Center of New; York, NY 10011, USA.

Abstract: Three nucleoside analogues, zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), are approved for use in the treatment of patients with HIV infection. This retrospective study compares the 3 drugs and examines the overall utility of antiretroviral therapy by way of comparisons to a no treatment (No Rx) group in patients with advanced HIV disease. Patients with advanced HIV disease were enrolled in didanosine (August 1989-December 1990) or zalcitabine (October 1990-February 1992) expanded access programmes; continued on zidovudine treatment despite fulfilling criteria for zidovudine failure or intolerance; or maintained on no antiretroviral treatment. Statistical analysis revealed that patients on nucleoside analogue therapy had fewer opportunistic infections (P = 0.001) than those who received no antiretroviral treatment. The Kaplan-Meier 12-month estimate of survival was significantly longer among patients who switched from zidovudine to zalcitabine but not among patients who switched to didanosine, when compared to the other 2 groups (P = 0.05).
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY Adult Aged Comparative Study Didanosine/ADVERSE EFFECTS/*THERAPEUTIC USE Female Follow-Up Studies Human Male Middle Age Retrospective Studies Support, Non-U.S. Gov't Survival Analysis Zalcitabine/ADVERSE EFFECTS/*THERAPEUTIC USE Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL CONTROLLED CLINICAL TRIAL JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/complications/KWDdrugtherapyadultagedcomparativestudydidanosine/adverseeffects/KWDtherapeuticusefemalefollow-upstudieshumanmalemiddleageretrospectivestudiessupport,non-uKWDsKWDgov'tsurvivalanalysiszalcitabine/adverseeffects/KWDtherapeuticusezidovudine/adverseeffects/KWDtherapeuticuseclinicaltrialcontrolledclinicaltrialjournalarticle
950830
M9580981

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .